Treatment of schizophrenia
Aspects of the invention relate generally to the treatment of schizophrenia and to monitoring for specific adverse reactions.
1. A method of treating a patient with iloperidone, said method comprising:
monitoring the patient specifically for one or more of the following hypersensitivity reactions while the patient is being treated with iloperidone: anaphylaxis; angioedema; throat tightness; oropharyngeal swelling; swelling of the face, lip, mouth, and/or tongue; or rash; and
if one or more of the recited hypersensitivity reactions occurs, then discontinuing treatment with iloperidone or reducing the dose of iloperidone.
2. The method of claim 1 , wherein the patient is being treated with iloperidone by oral delivery.
3. The method of claim 1 , wherein the patient is being treated with iloperidone at a dose of 12 to 24 mg per day.
4. A method of treating a patient with iloperidone, said method comprising:
administering iloperidone to the patient at a dose of 12 to 24 mg/d by oral delivery once daily or by intramuscular or subcutaneous injection of a depot form of iloperidone once monthly;
monitoring the patient specifically for one or more of the following hypersensitivity reactions while the patient is being treated with iloperidone: anaphylaxis; angioedema; throat tightness; oropharyngeal swelling; swelling of the face, lip, mouth, and/or tongue; or rash; and
if one or more of the recited hypersensitivity reactions occurs, then reducing the dose of iloperidone.
5. The method of claim 4 , wherein reducing the dose of iloperidone includes reducing the dose of iloperidone to 8 to 16 mg/d.
6. The method of claim 4 , wherein reducing the dose of iloperidone includes reducing the dose of iloperidone to 12 to 16 mg/d.
7. A method of reducing the frequency or severity of adverse events associated with iloperidone administration, said method comprising:
monitoring the patient specifically for one or more of the following hypersensitivity reactions while the patient is being treated with a dose of iloperidone: anaphylaxis; angioedema; throat tightness; oropharyngeal swelling; swelling of the face, lip, mouth, and/or tongue; or rash; and
if one or more of the recited hypersensitivity reactions occurs, then doing one of the following:
discontinuing treatment with iloperidone or reducing the dose of iloperidone; or
reducing the dose of iloperidone with which the patient is treated.
8. The method of claim 7 , wherein the patient is being treated with iloperidone by oral delivery.
9. The method of claim 7 , wherein the patient is being treated with iloperidone at a dose of 12 to 24 mg per day.
10. The method of claim 9 , wherein reducing the dose of iloperidone includes reducing the dose of iloperidone to 8 to 16 mg/d.
11. The method of claim 9 , wherein reducing the dose of iloperidone includes reducing the dose of iloperidone to 12 to 16 mg/d.